年轻乳腺癌患者中BRCA1/2突变携带者保乳治疗与乳房切除术的预后影响
该队列研究纳入1970至2003年间荷兰10个中心诊断的50岁以下浸润性乳腺癌女性,比较BRCA1/2突变携带者与非携带者接受保乳治疗(保乳手术加放疗)与乳房切除术后的预后。调整混杂因素后,保乳治疗与乳房切除术的总生存相似(非携带者HR=0.95,95%CI 0.85-1.07,P=0.41;BRCA1携带者HR=0.80,95%CI 0.42-1.51,P=0.50)。BRCA1携带者保乳治疗后10年局部复发风险为7.3%,非携带者为7.9%。结论提示保乳治疗可作为BRCA1突变携带者浸润性乳腺癌的安全局部治疗选择。
要点
- 调整混杂因素后,BRCA1突变携带者保乳治疗与乳房切除术的总生存无显著差异。
- BRCA1携带者保乳治疗后10年局部复发风险为7.3%,与非携带者的7.9%相近。
- BRCA2突变携带者样本量不足,无法得出结论。
核心结论
- 保乳治疗是BRCA1突变携带者浸润性乳腺癌的安全局部治疗选择。
研究设计与样本
- 队列研究,纳入1970至2003年荷兰10个中心诊断的50岁以下浸润性乳腺癌女性。
- 非携带者N=5820,BRCA1携带者N=191,BRCA2携带者N=70。
- 生存分析考虑竞争风险。
主要发现
- 非携带者中保乳治疗与乳房切除术的总生存相似(HR=0.95,95%CI 0.85-1.07,P=0.41)。
- BRCA1携带者中保乳治疗与乳房切除术的总生存相似(HR=0.80,95%CI 0.42-1.51,P=0.50)。
- BRCA1携带者保乳治疗后10年局部复发风险为7.3%,非携带者为7.9%。
- BRCA2突变携带者数据不足,无法得出结论。
临床怎么用
- 对于BRCA1突变携带的年轻浸润性乳腺癌患者,可考虑保乳治疗作为安全局部治疗选项。
- BRCA2突变携带者的保乳治疗决策需谨慎,因证据不足。
局限性
- BRCA2突变携带者样本量不足,无法得出可靠结论。
- BRCA1/2检测主要针对最常见突变,覆盖率约61%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effects of different types of surgery on breast cancer prognosis in germline BRCA1/BRCA2 mutation carriers compared with noncarriers. SUMMARY OF BACKGROUND DATA: Although breast-conserving therapy (breast-conserving surgery followed by radiotherapy) has been associated with more local recurrences than mastectomy, no differences in overall survival have been found in randomized trials performed in the general breast cancer population. Whether breast-conservation can be safely offered to BRCA1/2 mutation carriers is debatable. METHODS: The study comprised a cohort of women with invasive breast cancer diagnosed <50 years and treated between 1970 and 2003 in 10 Dutch centers. Germline DNA for BRCA1/2 testing of most-prevalent mutations (covering ∼61%) was mainly derived from paraffin-blocks. Survival analyses were performed taking into account competing risks. RESULTS: In noncarriers (N = 5820), as well as in BRCA1 (N = 191) and BRCA2 (N = 70) mutation carriers, approximately half of the patients received breast-conserving therapy. Patients receiving mastectomy followed by radiotherapy had prognostically worse tumor characteristics and more often received systemic therapy. After adjustment for these potential confounders, patients who received breast-conserving therapy had a similar overall survival compared with patients who received mastectomy, both in noncarriers (hazard ratio [HR] = 0.95, confidence interval [CI] = 0.85-1.07, P = 0.41) and BRCA1 mutation carriers (HR = 0.80, CI = 0.42-1.51, P = 0.50). Numbers for BRCA2 were insufficient to draw conclusions. The rate of local recurrences after breast-conserving therapy did not differ between BRCA1 carriers (10-year risk = 7.3%) and noncarriers (10-year risk = 7.9%). CONCLUSION: Our results, together with the available literature, provide reassurance that breast-conserving therapy is a safe local treatment option to offer to BRCA1 mutation carriers with invasive breast cancer.
引用
- van den Broek AJ, Schmidt MK, van 't Veer LJ, et al. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. Ann Surg. 2019. PMID: 29727326. doi:10.1097/SLA.0000000000002804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。